Savara, Inc. (SVRA)
5.565
-0.02
(-0.45%)
USD |
NASDAQ |
Aug 24, 16:00
5.565
0.00 (0.00%)
After-Hours: 20:00
Savara EPS Diluted (Quarterly) : -0.1587 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1587 |
| March 31, 2026 | -0.1472 |
| December 31, 2025 | -0.1341 |
| September 30, 2025 | -0.1366 |
| June 30, 2025 | -0.1405 |
| March 31, 2025 | -0.1232 |
| December 31, 2024 | -0.1348 |
| September 30, 2024 | -0.1145 |
| June 30, 2024 | -0.1218 |
| March 31, 2024 | -0.1114 |
| December 31, 2023 | -0.0895 |
| September 30, 2023 | -0.101 |
| June 30, 2023 | -0.0749 |
| March 31, 2023 | -0.0691 |
| December 31, 2022 | -0.0674 |
| September 30, 2022 | -0.068 |
| June 30, 2022 | -0.06 |
| March 31, 2022 | -0.0543 |
| December 31, 2021 | -0.0992 |
| September 30, 2021 | -0.0691 |
| June 30, 2021 | -0.0718 |
| March 31, 2021 | -0.1327 |
| December 31, 2020 | -0.2537 |
| September 30, 2020 | -0.1835 |
| June 30, 2020 | -0.1595 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.2688 |
| December 31, 2019 | -0.7238 |
| September 30, 2019 | -0.2972 |
| June 30, 2019 | -0.5707 |
| March 31, 2019 | -0.3363 |
| December 31, 2018 | -0.2928 |
| September 30, 2018 | -0.3726 |
| June 30, 2018 | -0.38 |
| March 31, 2018 | -0.879 |
| December 31, 2017 | -0.23 |
| September 30, 2017 | -0.28 |
| June 30, 2017 | -0.90 |
| March 31, 2017 | -115.50 |
| December 31, 2016 | -1.262 |
| September 30, 2016 | -84.70 |
| June 30, 2016 | -137.90 |
| March 31, 2016 | -4.20 |
| December 31, 2015 | -4.20 |
| September 30, 2015 | -4.20 |
| June 30, 2015 | -4.20 |
| March 31, 2015 | -4.20 |
| December 31, 2014 | -3.50 |
| September 30, 2014 | -4.20 |
| June 30, 2014 | -4.20 |
| March 31, 2014 | -4.20 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -8.444 |
| Insmed, Inc. | -0.0609 |
| United Therapeutics Corp. | 7.271 |
| Vertex Pharmaceuticals, Inc. | 4.310 |
| SELLAS Life Sciences Group, Inc. | -0.0508 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -40.23M |
| Total Expenses (Quarterly) | 40.23M |
| Enterprise Value | 1.006B |
| Earnings Yield | -10.36% |
| Normalized Earnings Yield | -10.36 |